List of works - Brett Langley

A brief review of recent Charcot-Marie-Tooth research and priorities

scientific article

A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties ⬇️

scientific article published on August 27, 2012

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

scientific article

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

scientific article published on November 2004

Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases

scientific article published on October 2013

Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy

scientific article published on 04 May 2016

Epigenetics in the nervous system

scientific article

Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies

scientific article

HDAC6 is a target for protection and regeneration following injury in the nervous system

scientific article

Harnessing hypoxic adaptation to prevent, treat, and repair stroke.

scientific article

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

scientific article

Introduction of a proximal Stat5 site in the murine alpha-lactalbumin promoter induces prolactin dependency in vitro and improves expression frequency in vivo

scientific article published in February 1999

Myostatin in muscle growth and repair.

scientific article

Myostatin inhibits myoblast differentiation by down-regulating MyoD expression.

scientific article

Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway.

scientific article published on January 2004

Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation

scientific article published on 01 December 2000

Nature and nurture meet at the epigenome to modulate disorders of the nervous system

scientific article published in June 2016

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

scientific article published on 19 October 2004

Oxidative stress-induced death in the nervous system: cell cycle dependent or independent?

scientific article published in September 2004

Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration

scientific article

Proteolytic processing of myostatin is auto-regulated during myogenesis

scientific article published in July 2005

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

scientific article

Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.

scientific article

Rescue of an MMTV transgene by co-integration reveals novel locus control properties of the ovine beta-lactoglobulin gene that confer locus commitment to heterogeneous tissues

scientific article published in May 1998

Sirtuin deacetylases as therapeutic targets in the nervous system

scientific article published on October 2013

Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury

scientific article

Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.

scientific article

Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.

scientific article published in August 2009

Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors

scientific article published in May 2009

Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function

scientific article published on 5 October 2015

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

scientific article published in July 2005

Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy.

scientific article published on 7 October 2004

List of works by Brett Langley

A brief review of recent Charcot-Marie-Tooth research and priorities

A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties ⬇️

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases

Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy

Epigenetics in the nervous system

Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies

HDAC6 is a target for protection and regeneration following injury in the nervous system

Harnessing hypoxic adaptation to prevent, treat, and repair stroke.

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

Introduction of a proximal Stat5 site in the murine alpha-lactalbumin promoter induces prolactin dependency in vitro and improves expression frequency in vivo

Myostatin in muscle growth and repair.

Myostatin inhibits myoblast differentiation by down-regulating MyoD expression.

Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway.

Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation

Nature and nurture meet at the epigenome to modulate disorders of the nervous system

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

Oxidative stress-induced death in the nervous system: cell cycle dependent or independent?

Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration

Proteolytic processing of myostatin is auto-regulated during myogenesis

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.

Rescue of an MMTV transgene by co-integration reveals novel locus control properties of the ovine beta-lactoglobulin gene that confer locus commitment to heterogeneous tissues

Sirtuin deacetylases as therapeutic targets in the nervous system

Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury

Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.

Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.

Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors

Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy.